276 related articles for article (PubMed ID: 29311579)
1. Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ.
Jang JY; Bae H; Lee YJ; Choi YI; Kim HJ; Park SB; Suh SW; Kim SW; Han BW
Sci Rep; 2018 Jan; 8(1):31. PubMed ID: 29311579
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW
Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850
[TBL] [Abstract][Full Text] [Related]
3. Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs.
Lee MA; Tan L; Yang H; Im YG; Im YJ
Sci Rep; 2017 Dec; 7(1):16837. PubMed ID: 29203903
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation.
Jang JY; Kim H; Kim HJ; Suh SW; Park SB; Han BW
Sci Rep; 2019 Aug; 9(1):11168. PubMed ID: 31371757
[TBL] [Abstract][Full Text] [Related]
5. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
[TBL] [Abstract][Full Text] [Related]
6. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain.
Amato AA; Rajagopalan S; Lin JZ; Carvalho BM; Figueira AC; Lu J; Ayers SD; Mottin M; Silveira RL; Souza PC; Mourão RH; Saad MJ; Togashi M; Simeoni LA; Abdalla DS; Skaf MS; Polikparpov I; Lima MC; Galdino SL; Brennan RG; Baxter JD; Pitta IR; Webb P; Phillips KJ; Neves FA
J Biol Chem; 2012 Aug; 287(33):28169-79. PubMed ID: 22584573
[TBL] [Abstract][Full Text] [Related]
7. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
[TBL] [Abstract][Full Text] [Related]
8. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.
Choi JH; Banks AS; Kamenecka TM; Busby SA; Chalmers MJ; Kumar N; Kuruvilla DS; Shin Y; He Y; Bruning JB; Marciano DP; Cameron MD; Laznik D; Jurczak MJ; Schürer SC; Vidović D; Shulman GI; Spiegelman BM; Griffin PR
Nature; 2011 Sep; 477(7365):477-81. PubMed ID: 21892191
[TBL] [Abstract][Full Text] [Related]
9. CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo.
Ming Y; Hu X; Song Y; Liu Z; Li J; Gao R; Zhang Y; Mei H; Guo T; Xiao L; Wang B; Wu C; Xiao X
PLoS One; 2014; 9(7):e102102. PubMed ID: 25004107
[TBL] [Abstract][Full Text] [Related]
10. Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity.
Guasch L; Sala E; Valls C; Blay M; Mulero M; Arola L; Pujadas G; Garcia-Vallvé S
J Comput Aided Mol Des; 2011 Aug; 25(8):717-28. PubMed ID: 21691811
[TBL] [Abstract][Full Text] [Related]
11. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
Sauer S
Trends Pharmacol Sci; 2015 Oct; 36(10):688-704. PubMed ID: 26435213
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis for the Regulation of PPARγ Activity by Imatinib.
Jang JY; Kim HJ; Han BW
Molecules; 2019 Oct; 24(19):. PubMed ID: 31581474
[TBL] [Abstract][Full Text] [Related]
13. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
[TBL] [Abstract][Full Text] [Related]
14. The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activity.
Rocha RF; Rodrigues T; Menegatti ACO; Bernardes GJL; Terenzi H
Bioorg Chem; 2020 Jul; 100():103927. PubMed ID: 32422389
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.
Liu C; Feng T; Zhu N; Liu P; Han X; Chen M; Wang X; Li N; Li Y; Xu Y; Si S
Sci Rep; 2015 Apr; 5():9530. PubMed ID: 25827822
[TBL] [Abstract][Full Text] [Related]
16. Study of the interactions between Edaglitazone and Ciglitazone with PPARγ and their antiplatelet profile.
Muñoz-Gutiérrez C; Sepúlveda C; Caballero J; Palomo I; Fuentes E
Life Sci; 2017 Oct; 186():59-65. PubMed ID: 28757415
[TBL] [Abstract][Full Text] [Related]
17. Mode of peroxisome proliferator-activated receptor γ activation by luteolin.
Puhl AC; Bernardes A; Silveira RL; Yuan J; Campos JL; Saidemberg DM; Palma MS; Cvoro A; Ayers SD; Webb P; Reinach PS; Skaf MS; Polikarpov I
Mol Pharmacol; 2012 Jun; 81(6):788-99. PubMed ID: 22391103
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow.
Kouskoumvekaki I; Petersen RK; Fratev F; Taboureau O; Nielsen TE; Oprea TI; Sonne SB; Flindt EN; Jónsdóttir SÓ; Kristiansen K
J Chem Inf Model; 2013 Apr; 53(4):923-37. PubMed ID: 23432662
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
[TBL] [Abstract][Full Text] [Related]
20. Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma.
Tsukahara T; Tsukahara R; Yasuda S; Makarova N; Valentine WJ; Allison P; Yuan H; Baker DL; Li Z; Bittman R; Parrill A; Tigyi G
J Biol Chem; 2006 Feb; 281(6):3398-407. PubMed ID: 16321982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
